Headline: UNCAPTIONED: Weight-Loss Drug Wegovy comes to China Amid Rising Demand
Caption:
Weight-Loss Drug Wegovy comes to China Amid Rising Demand. Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it against rival Eli Lilly, whose treatment, Zepbound, is yet to hit shelves in the world’s second-largest pharmaceutical market. With over 180 million people living with obesity in China, the demand for such solutions is immense. Wegovy will cost 1,400 yuan, or about $194, for four injections—a fraction of its $1,349 price in the U.S. However, Chinese patients will bear the full cost, as the drug isn’t covered by national healthcare insurance. Research shows that Wegovy can help patients shed over 10% of their body weight, adding significant appeal in a country grappling with obesity. Novo Nordisk’s entry marks a major step in the competitive landscape for weight-loss treatments in China.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT
Keywords: Health & Wellbeing,Wegovy,weight-loss drug,China,Novo Nordisk,eli Lilly,Zepbound,rival,obesity,sttruggling,injections,thousand,yuan,dollars,not covered,national health,pay,full price,treatments,demand,solutions,immense,cost,cheaper
PersonInImage: